文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌当代放疗技术后患者报告结局的比较研究

A comparative study of patient-reported outcomes after contemporary radiation techniques for prostate cancer.
PubMed 文献 · Radiother Oncol · 2022-04-29

纳入7项前瞻性临床试验中648例低危和中危前列腺癌患者,比较立体定向消融放疗、高剂量率近距离治疗单药与高剂量率近距离治疗增量三种策略在12个月时健康相关生活质量恶化情况,结果显示SABR和HDR单药在泌尿和性功能域恶化比例低于HDR增量。

要点

  • SABR组泌尿域MID恶化38%,HDR单药组40%,HDR增量组55%。
  • SABR组性功能域MID恶化38%,HDR单药组42%,HDR增量组47%。
  • 多因素分析中SABR和HDR单药相比HDR增量与更少泌尿和性功能域恶化相关。

核心结论

  • 低危和中危前列腺癌的近期单药治疗方式与患者健康相关生活质量的保留相关。
  • 疗效、毒性和健康相关生活质量问题最终最好通过随机临床试验来回答。

研究设计与样本

  • 纳入7项前瞻性临床试验中接受治疗的648例低危或中危前列腺癌患者。
  • 三种策略分别为SABR组288例、HDR单药组173例和HDR增量组187例。
  • 所有试验均在基线和12个月时使用扩展前列腺癌指数综合量表(EPIC)前瞻性测量健康相关生活质量。
  • 最小重要差异(MID)定义为12个月时健康相关生活质量评分较基线下降≥0.5个基线标准差。
  • 采用广义估计方程的单因素和多因素逻辑回归比较组间发生MID的患者比例,并进行系列敏感性分析。

主要发现

  • 单因素和多因素分析中,SABR组和HDR单药组相比HDR增量组,泌尿域MID恶化比例分别为38%、40% vs 55%(SABR vs HDR增量:OR 0.543,95%CI 0.320-0.922,p=0.024;HDR单药 vs HDR增量:OR 0.468,95%CI 0.432-0.507,p<0.001)。
  • 单因素和多因素分析中,SABR组和HDR单药组相比HDR增量组,性功能域MID恶化比例分别为38%、42% vs 47%(SABR vs HDR增量:OR 0.762,95%CI 0.645-0.900,p=0.001;HDR单药 vs HDR增量:OR 0.786,95%CI 0.650-0.949,p=0.012)。
  • 上述发现在多种敏感性分析中保持稳健。

关键数值与推荐

  • MID定义为12个月时EPIC评分较基线下降≥0.5个基线标准差。
  • 泌尿域MID恶化:SABR组38% vs HDR增量组55%,OR 0.543(95%CI 0.320-0.922,p=0.024)。
  • 泌尿域MID恶化:HDR单药组40% vs HDR增量组55%,OR 0.468(95%CI 0.432-0.507,p<0.001)。
  • 性功能域MID恶化:SABR组38% vs HDR增量组47%,OR 0.762(95%CI 0.645-0.900,p=0.001)。
  • 性功能域MID恶化:HDR单药组42% vs HDR增量组47%,OR 0.786(95%CI 0.650-0.949,p=0.012)。

临床怎么用

  • 原文结论指出低危和中危前列腺癌的近期单药治疗方式与患者健康相关生活质量的保留相关。
  • 原文结论指出疗效、毒性和健康相关生活质量问题最终最好通过随机临床试验来回答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aim to compare health-related quality of life (HRQoL) deterioration at 12 months in low-and intermediate-risk prostate cancer (PCa) patients treated with stereotactic ablative radiotherapy (SABR), high dose-rate brachytherapy (HDR) monotherapy and HDR boost. MATERIAL AND METHODS: Patients treated as part of 7 prospective clinical trials were included. All patients had low-or intermediate-risk PCa. Three strategies were considered: SABR, HDR monotherapy and HDR boost. HRQoL was prospectively measured at baseline and 12 months in all trials, using the Expanded Prostate Index Composite (EPIC). A minimally important difference (MID) was defined as a deterioration of HRQoL scores at 12 months compared to baseline ≥0.5 standard deviation of baseline score. Univariate and multivariable logistic regression using generalized estimating equations were used to compare the proportion of patients having MID between groups. A set of sensitivity analyses was conducted. RESULTS: 648 patients were included: 288, 173 and 187 respectively in the SABR, HDR monotherapy and HDR boost group. On univariate and multivariable analyses, SABR and HDR monotherapy compared to HDR boost, were associated with less deterioration in the urinary (38%, 40% vs. 55%; OR:0.543, 95%CI:0.320-0.922, p = 0.024; OR:0.468, 95%CI:0.432-0.507, p < 0.001) and sexual domains (38%, 42% vs. 47%; OR:0.762, 95%CI:0.645-0.900, p = 0.001; OR: 0.786, 95%CI:0.650-0.949, p = 0.012). These findings wererobust to a variety ofsensitivity analyses. CONCLUSION: Recent monotherapeutic approaches for low- and intermediate-risk PCa are associated with the preservation of patients HRQoL. Ultimately, the questions of efficacy, toxicity, and HRQoL will be best answered by a randomized clinical trial.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Helou J, Morton G, Kiss A, et al. A comparative study of patient-reported outcomes after contemporary radiation techniques for prostate cancer. Radiother Oncol. 2022. PMID: 35500786. doi:10.1016/j.radonc.2022.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。